The Atrial Fibrillation drugs in development market research report provides comprehensive information on the therapeutics under development for Atrial Fibrillation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Atrial Fibrillation. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Atrial Fibrillation and features dormant and discontinued products.

GlobalData tracks 34 drugs in development for Atrial Fibrillation by 30 companies/universities/institutes. The top development phase for Atrial Fibrillation is preclinical with 13 drugs in that stage. The Atrial Fibrillation pipeline has 33 drugs in development by companies and one by universities/ institutes. Some of the companies in the Atrial Fibrillation pipeline products market are: Acesion Pharma, Toa Eiyo and Bristol-Myers Squibb.

The key targets in the Atrial Fibrillation pipeline products market include Beta 1 Adrenergic Receptor (Beta 1 Adrenoreceptor or ADRB1), Potassium Channel (KCN), and Muscarinic Gated Atrial Potassium Channel (IKACh).

The key mechanisms of action in the Atrial Fibrillation pipeline product include Potassium Channel (KCN) Blocker with three drugs in Filing rejected/Withdrawn. The Atrial Fibrillation pipeline products include nine routes of administration with the top ROA being Oral and four key molecule types in the Atrial Fibrillation pipeline products market including Small Molecule, and Protein.

Atrial Fibrillation overview

Atrial fibrillation is an irregular and often rapid heart rate that commonly causes poor blood flow to the body. Symptoms include decreased blood pressure, weakness, lightheadedness, confusion and chest pain. The predisposing factors include age, heart disease, high blood pressure, family history and drinking alcohol. Treatments for atrial fibrillation may include medications and surgery.

For a complete picture of Atrial Fibrillation’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.